These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29326015)

  • 1. Ecchymosis and/or haematoma formation after prophylactic administration of subcutaneous enoxaparin in the abdomen or arm of the critically ill patient.
    Jareño-Collado R; Sánchez-Sánchez MM; Fraile-Gamo MP; García-Crespo N; Barba-Aragón S; Bermejo-García H; Sánchez-Izquierdo R; Sánchez-Muñoz EI; López-López A; Arias-Rivera S
    Enferm Intensiva (Engl Ed); 2018; 29(1):4-13. PubMed ID: 29326015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of abdominal and arm areas in patients receiving subcutaneous heparin in terms of development of pain, hematoma, and ecchymosis.
    Cengiz Z; Özkan M
    J Vasc Nurs; 2018 Dec; 36(4):208-215. PubMed ID: 30458944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Administration Protocol of Subcutaneous Enoxaparin Injection on Formation of Ecchymosis.
    Uzun S; Aciksoz S; Arslan F; Yildiz C; Akyol M
    Orthop Nurs; 2016; 35(2):120-5; quiz 126-7. PubMed ID: 27028689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioactivity of enoxaparin in critically ill patients with normal renal function.
    Gouya G; Palkovits S; Kapiotis S; Madl C; Locker G; Stella A; Wolzt M; Heinz G
    Br J Clin Pharmacol; 2012 Nov; 74(5):806-14. PubMed ID: 23227470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two needle sizes for subcutaneous administration of enoxaparin: effects on size of hematomas and pain on injection.
    Robb DM; Kanji Z
    Pharmacotherapy; 2002 Sep; 22(9):1105-9. PubMed ID: 12222545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial.
    Vahtera A; Valkonen M; Huhtala H; Pettilä V; Kuitunen A
    Thromb Res; 2017 Oct; 158():71-75. PubMed ID: 28846877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U;
    J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practice Patterns of Venous Thromboembolism Prophylaxis in Underweight, Critically Ill Patients with Neurologic Injury.
    Betthauser K; Pope H; Gowan M; Human T
    Neurocrit Care; 2017 Aug; 27(1):96-102. PubMed ID: 28097621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
    Diab YA; Ramakrishnan K; Ferrell B; Chounoune R; Alfares FA; Endicott KM; Rooney S; Corcoran J; Zurakowski D; Berger JT; Shankar V; Nath DS
    Pediatr Crit Care Med; 2017 May; 18(5):e207-e214. PubMed ID: 28296662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients.
    Abbas MS
    Indian J Crit Care Med; 2017 Jul; 21(7):419-423. PubMed ID: 28808360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle haematoma due to antithrombotic treatment for ischaemic stroke.
    Hiraga A; Nakagawa Y; Kamitsukasa I; Suzuki T; Kuwabara S
    J Clin Neurosci; 2015 Jul; 22(7):1160-3. PubMed ID: 25882254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of cold on the occurrence of bruising, haematoma and pain at the injection site in subcutaneous low molecular weight heparin.
    Kuzu N; Ucar H
    Int J Nurs Stud; 2001 Feb; 38(1):51-9. PubMed ID: 11137723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
    Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
    J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rectus sheath haematoma: enoxaparin-related complication.
    Velicki L; Cemerlić-Adić N; Bogdanović D; Mrdanin T
    Acta Clin Belg; 2013; 68(2):147-9. PubMed ID: 23967729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin-associated severe retroperitoneal bleeding and abdominal compartment syndrome: a report of two cases.
    Dabney A; Bastani B
    Intensive Care Med; 2001 Dec; 27(12):1954-7. PubMed ID: 11797033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
    Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
    Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury.
    Hebbeler SL; Marciniak CM; Crandall S; Chen D; Nussbaum S; Mendelewski S
    J Spinal Cord Med; 2004; 27(3):236-40. PubMed ID: 15478526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
    Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
    Ann Intern Med; 2004 Jun; 140(11):867-73. PubMed ID: 15172900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.